Drug intelligence / Profile preview

HZB0071

Development stage: Unknown
Lead developer: Harbin Treasure Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HZB0071 is a small molecule dihydropyrazole azepine compound developed by Harbin Treasure Pharmaceutical (also known as Zhenbaodao Pharmaceutical). It functions as an inhibitor of AKT kinase and modulates the PI3K/ALK/mTOR signaling pathway, which plays a critical role in cell growth, proliferation, and survival. By targeting these pathways, HZB0071 is designed to exert anti-tumor effects across a variety of cancer types. According to company pipeline information, the drug has completed Phase 3 development milestones and is currently in the process of preparing for an Investigational New Drug (IND) filing.

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)mTOR (Mammalian target of rapamycin kinase)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)AKT (RAC-alpha serine/threonine-protein kinase)

Beyond the preview

Go deeper on HZB0071.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HZB0071.

Explore the full profile